Free radicals, antioxidant defense systems, and schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 200-206

  Wu, Jing Qin ^a,b,c   Kosten, Thomas R ^c,d,e   Zhang, Xiang Yang ^c,d,e  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c PEKING UNIVERSITY   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antioxidant defense systems; Free radicals; Neuroleptics; Oxidative stress; Schizophrenia; Tardive dyskinesia

Indexed keywords

4 HYDROXYNONENAL; ALBUMIN; ALPHA TOCOPHEROL; ASCORBIC ACID; BILIRUBIN; CARBON CENTERED RADICAL; CATALASE; CLOZAPINE; FREE RADICAL; GINKGO BILOBA EXTRACT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE PEROXIDASE; HALOPERIDOL; HYDROGEN PEROXIDE; HYDROXYL RADICAL; MALONALDEHYDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RISPERIDONE; SULFUR CENTERED RADICAL; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOREDOXIN; UNCLASSIFIED DRUG; URIC ACID;

ALBUMIN BLOOD LEVEL; ARTICLE; AUTOPSY; BILIRUBIN BLOOD LEVEL; BRAIN REGION; DEFENSE MECHANISM; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FREE RADICAL METABOLISM; HUMAN; LIPID PEROXIDATION; METABOLISM; METABOLITE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; URIC ACID BLOOD LEVEL; VITAMIN BLOOD LEVEL;

4-HYDROXYNONENAL; 8-ISOPGF2 ALPHA; ALPHA-TOCOPHEROL; ANTIOXIDANT DEFENSE SYSTEMS; CAT; CATALASE; COMPUTED TOMOGRAPHY; CT; EGB; FREE RADICALS; GINKGO BILOBA EXTRACT; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GR; GSH; GSH-PX; GSSG; H(2)O(2); HNE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; ISOPROSTANE--8-EPI-PROSTAGLANDIN F2 ALPHA; MALONYLDIALDEHYDE; MDA; NADPH; NEUROLEPTICS; NICOTINAMIDE ADENINE DINUCLEOTIDE-PHOSPHATE; NITRIC OXIDE; NO; NOS; O(2)(-); OH; OXIDATIVE STRESS; OXIDIZED FORM GLUTATHIONE DISULFIDE; POLYUNSATURATED FATTY ACIDS; PUFA; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; REDOX; REDUCED GLUTATHIONE; REDUCTION-OXIDATION; ROS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SOD; SUPEROXIDASE DISMUTASES; SUPEROXIDE RADICAL; TARDIVE DYSKINESIA; TAS; TBARS; TD; THIOBARBITURIC ACID REACTIVE SUBSTANCES; THIOREDOXIN; THROMBOXANE B2; TOTAL ANTIOXIDANT STATUS; TRX; TXB2; VITAMIN E;

ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; FREE RADICALS; HUMANS; LIPID PEROXIDATION; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 84883551131     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.02.015     Document Type: Article

References (100)

1. Abdalla D.S., Monteiro H.P., Oliveira J.A., Bechara E.J. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986, 32:805-807.
2. Adler L.A., Peselow E., Rotrosen J., Duncan E., Lee M., Rosenthal M., et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993, 150:1405-1407.
3. Adler L.A., Edson R., Lavori P., Peselow E., Duncan E., Rosenthal M., et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998, 43:868-872.
4. Akyol O., Yanik M., Elyas H., Namli M., Canatan H., Akin H., et al. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:123-131.
5. Altuntas I., Aksoy H., Coskun I., Caykoylu A., Akcay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med 2000, 38:1277-1281.
6. Berg D., Youdim M.B., Riederer P. Redox imbalance. Cell Tissue Res 2004, 318:201-213.
7. Bernstein H.G., Bogerts B., Keilhoff G. The many faces of nitric oxide in schizophrenia. Schizophr Res 2005, 78:69-86.
8. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35:878-893.
9. Buckman T.D., Kling A.S., Eiduson S., Sutphin M.S., Steinberg A. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol Psychiatry 1987, 22:1349-1356.
10. Buckman T.D., Kling A., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 1990, 31:1-14.
11. Carpenter W.T. The deficit syndrome. Am J Psychiatry 1994, 151:327-329.
12. Ciobica A., Padurariu M., Dobrin I., Stefanescu C., Dobrin R. Oxidative stress in schizophrenia - focusing on the main markers. Psychiatr Danub 2011, 23:237-245.
13. Crow T.J., Cross A.J., Johnstone E.C., Owen F., Owens D.G., Waddington J.L. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?. J Clin Psychopharmacol 1982, 2:336-340.
14. Davies K.J. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 1995, 61:1-31.
15. Dietrich-Muszalska A., Olas B. Isoprostenes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 2009, 10:27-33.
16. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728.
17. Egan M.F., Hyde T.M., Albers G.W., Elkashef A., Alexander R.C., Reeve A., et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992, 149:773-777.
18. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:512-515.
19. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011, 14:123-130.
20. Golse B., Debray-Ritzen P., Puget K., Michelson A.M. Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses. Nouv Presse Med 1977, 6:2449.
21. Griendling K.K., Sorescu D., Lassegue B., Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000, 20:2175-2183.
22. Halliwell B. Phagocyte-derived reactive species: salvation or suicide?. Trends Biochem Sci 2006, 31:509-515.
23. Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans 2007, 35:1147-1150.
24. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68. [image 5].
25. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001, 6:66-73.
26. Hitzeroth A., Niehaus D.J., Koen L., Botes W.C., Deleuze J.F., Warnich L. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:664-672.
27. Hoffer A., Osmond H., Smythies J. Schizophrenia; a new approach. II. Result of a year's research. J Ment Sci 1954, 100:29-45.
28. Hori H., Ohmori O., Shinkai T., Kojima H., Okano C., Suzuki T., et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000, 23:170-177.
29. Horton A.A., Fairhurst S. Lipid peroxidation and mechanisms of toxicity. Crit Rev Toxicol 1987, 18:27-79.
30. Kang S.G., Choi J.E., An H., Park Y.M., Lee H.J., Han C., et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1844-1847.
31. Kohen R., Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002, 30:620-650.
32. 2-induced higher order chromatin degradation: a novel mechanism of oxidative genotoxicity. J Biosci 2003, 28:57-60.
33. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
34. Lau Y.S., Petroske E., Meredith G.E., Wang J.Q. Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats. Neuropharmacology 2003, 45:986-994.
35. Lee B.H., Kim Y.K. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr Res 2008, 104:36-43.
36. Li X.F., Zheng Y.L., Xiu M.H., Chen da C., Kosten T.R., Zhang X.Y. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1064-1067.
37. Liu H., Wang C., Chen P.H., Zhang B.S., Zheng Y.L., Zhang C.X., et al. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:692-696.
38. Lockwood T.D. Redox control of protein degradation. Antioxid Redox Signal 2000, 2:851-878.
39. Lohmueller K.E., Pearce C.L., Pike M., Lander E.S., Hirschhorn J.N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003, 33:177-182.
40. Lohr J.B. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry 1991, 48:1097-1106.
41. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995, 31:159-165.
42. Lohr J.B., Caligiuri M.P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996, 57:167-173.
43. Lohr J.B., Cadet J.L., Lohr M.A., Larson L., Wasli E., Wade L., et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988, 14:291-296.
44. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990, 28:535-539.
45. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998, 43:674-679.
46. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:463-493.
47. Matsuzawa D., Obata T., Shirayama Y., Nonaka H., Kanazawa Y., Yoshitome E., et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 2008, 3:e1944.
48. McCreadie R.G., MacDonald E., Wiles D., Campbell G., Paterson J.R. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br J Psychiatry 1995, 167:610-617.
49. Mico J.A., Rojas-Corrales M.O., Gibert-Rahola J., Parellada M., Moreno D., Fraguas D., et al. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry 2011, 11:26.
50. Miller D.M., Buettner G.R., Aust S.D. Transition metals as catalysts of "autoxidation" reactions. Free Radic Biol Med 1990, 8:95-108.
51. Morgenstern H., Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993, 50:723-733.
52. Mukerjee S., Mahadik S.P., Scheffer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19:19-26.
53. Nel A., Harvey B.H. Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol 2003, 14:251-255.
54. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876.
55. Nordberg J., Arner E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001, 31:1287-1312.
56. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010, 479:317-320.
57. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003, 37:43-51.
58. Peet M., Laugharne J., Rangarajan N., Reynolds G.P. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993, 8:151-153.
59. Phillips M., Sabas M., Greenberg J. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. J Clin Pathol 1993, 46:861-864.
60. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007, 41:372-386.
61. Raffa M., Atig F., Mhalla A., Kerkeni A., Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011, 11:124.
62. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
63. Reddy R. Antioxidant therapeutics for schizophrenia. Antioxid Redox Signal 2011, 15:2047-2055.
64. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996, 55:33-43.
65. Reddy R., Sahebarao M.P., Mukherjee S., Murthy J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991, 30:409-412.
66. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003, 62:205-212.
67. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., Sarandol E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1164-1169.
68. Shinkai T., De Luca V., Zai G., Shaikh S., Matsumoto C., Arnold P.D., et al. No association between the Pro197Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia. Psychiatr Genet 2004, 14:177-180.
69. Shinkai T., Muller D.J., De Luca V., Shaikh S., Matsumoto C., Hwang R., et al. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Res 2006, 141:123-128.
70. Stadtman E.R., Levine R.L. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003, 25:207-218.
71. Stoklasova A., Zapletalek M., Kudrnova K., Randova Z. Glutathione peroxidase activity in the blood in chronic schizophrenia. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl 1986, 29:103-108.
72. Suboticanec K., Folnegovic-Smalc V., Korbar M., Mestrovic B., Buzina R. Vitamin C status in chronic schizophrenia. Biol Psychiatry 1990, 28:959-966.
73. Tamminga C.A., Holcomb H.H. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005, 10:27-39.
74. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide 2002, 7:297-300.
75. Terpstra M., Vaughan T.J., Ugurbil K., Lim K.O., Schulz S.C., Gruetter R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA 2005, 18:276-282.
76. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998, 155:1207-1213.
77. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
78. Vendemiale G., Grattagliano I., Altomare E. An update on the role of free radicals and antioxidant defense in human disease. Int J Clin Lab Res 1999, 29:49-55.
79. Virit O., Altindag A., Yumru M., Dalkilic A., Savas H.A., Selek S., et al. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009, 60:87-93.
80. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
81. Wood S.J., Berger G.E., Wellard R.M., Proffitt T.M., McConchie M., Berk M., et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis 2009, 33:354-357.
82. Wu Z., Zhang X.Y., Wang H., Tang W., Xia Y., Zhang F., et al. Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2011, 36:34-38.
83. Yamada K., Kanba S., Anamizu S., Ohnishi K., Ashikari I., Yagi G., et al. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol Med 1997, 27:1223-1225.
84. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011, 15:2011-2035.
85. Yao J.K., Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal 2011, 15:1999-2002.
86. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998, 32:385-391.
87. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998, 32:1-8.
88. Yao J.K., Reddy R., van Kammen D.P. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998, 80:29-39.
89. Yao J.K., Reddy R.D., van Kammen D.P. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999, 45:1512-1515.
90. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000, 97:137-151.
91. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006, 22:83-93.
92. Zai C.C., Tiwari A.K., Basile V., de Luca V., Muller D.J., Voineskos A.N., et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:50-56.
93. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003, 117:85-88.
94. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol 2003, 23:128-131.
95. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006, 81:291-300.
96. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., et al. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry 2007, 68:754-760.
97. Zhang X.Y., Chen da C., Xiu M.H., Wang F., Qi L.Y., Sun H.Q., et al. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res 2009, 113:151-157.
98. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 2010, 53:112-124.
99. Zhang W.F., Tan Y.L., Zhang X.Y., Chan R.C., Wu H.R., Zhou D.F. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72:615-621.
100. Zhang X.Y., Zhou D.F., Shen Y.C., Zhang P.Y., Zhang W.F., Liang J., et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012, 62:1928-1934.